Answers are grounded in this paper and cite their sources.
First-in-human evaluation demonstrates a safe and feasible outpatient infusion option in chronic kidney disease, implying further research is needed.
This novel, fully subcutaneous IO device appears to be a feasible, usable, and safe option for short-term infusion therapy in patients with CKD or challenging venous access. These findings support further investigation into its use as a long-term intraosseous vascular access option.
No takes yet. Share an insight, caveat, or question.
Ulloa et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: